FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production
27.9.2019 18:00:00 EEST | Business Wire | Press release
RoboSense, the pioneering Smart LiDAR Sensor provider, announced a partnership with FAW ("First Automobile Works"), the world's leading automotive OEM (Original Equipment Manufacturer), and showcased the milestone achievement of last year’s cooperation: the first batch of world’s first solid-state Smart LiDAR Sensor RS-LiDAR-M1 on September 25. The deal is to include RS-LiDAR-M1 as core component into FAW's proprietary next-generation autonomous driving system development, therefore accelerating the serial production of the world's first automotive-grade solid-state MEMS-based Smart LiDAR Sensor, in order to promote Level 3 vehicle autonomy and above.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190927005229/en/
FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production (Photo: Business Wire)
The final commercialized version of RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based Smart LiDAR Sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip). It transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems. The RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but its built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.
Unlike RoboSense Smart LiDAR Sensor, when mechanical LiDAR is used on a vehicle, a computer-sized ECU must also be used to operate the algorithms. Compared with ECUs, the RoboSense dedicated SoC built into the Smart LiDAR Sensor not only withstands strong bumps and jolts in the vehicle, but is also small and light-weight. The RoboSense Smart LiDAR Sensor's built-in SoC can largely reduce more power consumption while improving performance compared to automotive ECUs, saving much more passenger space at the same time.
The RS-LiDAR-M1 is cleanly designed in a streamlined body that allows it to be easily embedded onto any part of the vehicle for the complete aesthetics of automobile.
Serial produced RoboSense Smart LiDAR Sensor costs only hundreds of dollars each, based on its deployment of revolutionary MEMS micro-mirror scanning structure and simplified manufacturing and streamlines production, while maintaining high product quality and reliability to meet exacting OEM requirements.
Fengjun Li, Director of Intelligent Connected Vehicle Development Institute, FAW, said, "China is standing at the front of the world's autonomous driving development. Our cooperation with RoboSense demonstrates our confidence in Smart LiDAR Sensor for Level 3 vehicle autonomy and above, and accelerates the commercialized development of our proprietary next-generation autonomous driving system”.
"The RS-LiDAR-M1 is a revolutionary product developed upon more than ten years of research development accumulated by the RoboSense team. We believe the partnership will enhance the serial production ability of automotive-grade Smart LiDAR Sensor for autonomous driving,” said Steven Qiu ChuanXin, RoboSense Founder and CEO.
At the signing ceremony, the closest to commercialized version of Smart LiDAR Sensor RS-LiDAR-M1 delivered by RoboSense will be used for FAW's automotive-grade testing and self-driving passenger cars research development. The current version has greatly improved performance while reducing the size to only the half of the former demo showcased on CES 2019, which can be easily integrated into any part of the vehicle body. More details of the latest version will be coming soon.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving.
For more information about RoboSense please visit: https://www.robosense.ai/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190927005229/en/
Contact information
Media:
Cassie Gong, PR Manager
sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom